Invitrogen Takes a Step Further Into Dx Reagent Market With Caltag Buy | GenomeWeb

Continuing its shopping spree for new protein-related technologies — and gaining another foothold in the diagnostic reagents market — Invitrogen this week said it will pay $20 million in cash to acquire Caltag Laboratories, a California manufacturer of immunological reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.